{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Boyle TA"],"funding":["Novartis Pharma","National Cancer Institute","NCI NIH HHS","National Institutes of Health"],"pagination":["225-237"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6943158"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["<h4>Background</h4>For the advancement of cancer research, the collection of tissue specimens from drug-resistant tumors after targeted therapy is crucial. Although patients with lung cancer are often provided targeted therapy, post-therapy specimens are not routinely collected due to the risks of collection, limiting the study of targeted therapy resistance mechanisms. Posthumous rapid tissue donation (RTD) is an expedient collection process that provides an opportunity to understand treatment-resistant lung cancers.<h4>Methods</h4>Consent to participate in the thoracic RTD protocol was obtained during patient care. When death occurred, tumor and paired non-tumor, cytology, and blood specimens were collected within 48 hours and preserved as formalin-fixed and frozen specimens. Tissue sect"],"journal":["Cancer medicine"],"pubmed_title":["A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses."],"pmcid":["PMC6943158"],"funding_grant_id":["R21 CA194932","P30‐CA76292","R21CA194932","P30 CA076292"],"pubmed_authors":["Savchenko A","Quinn GP","Mendell K","Munoz-Antonia T","Chiappori AA","Creelan BC","Hair LS","Gray JE","Chiang DY","Wong CC","Duarte LF","Teer JK","Antonia SJ","Gorgun G","Charette L","Boyle TA","Saller JJ","Singh AP","Haura EB","Leary R","Schabath MB"],"additional_accession":[]},"is_claimable":false,"name":"A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.","description":"<h4>Background</h4>For the advancement of cancer research, the collection of tissue specimens from drug-resistant tumors after targeted therapy is crucial. Although patients with lung cancer are often provided targeted therapy, post-therapy specimens are not routinely collected due to the risks of collection, limiting the study of targeted therapy resistance mechanisms. Posthumous rapid tissue donation (RTD) is an expedient collection process that provides an opportunity to understand treatment-resistant lung cancers.<h4>Methods</h4>Consent to participate in the thoracic RTD protocol was obtained during patient care. When death occurred, tumor and paired non-tumor, cytology, and blood specimens were collected within 48 hours and preserved as formalin-fixed and frozen specimens. Tissue sect","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jan","modification":"2025-05-29T21:27:24.102Z","creation":"2025-05-29T21:27:24.102Z"},"accession":"S-EPMC6943158","cross_references":{"pubmed":["31747139"],"doi":["10.1002/cam4.2670"]}}